Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest DiagnosticsFRA:QDI -1.17%78 PE Ratio (TTM) is 23.27 as of Jul. 21, 2026, which is 23% above its 10-year median of 18.97. GuruFocus rates FRA:QDI with a GF Score™ of 78/100 and a GF Value™ of €166.27 (Fairly Valued). The stock has 8 warning signs investors should review. Among 94 Medical Diagnostics & Research companies, Quest Diagnostics ranks better than 64.89% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-21), Quest Diagnostics's share price is
€181.10.
Quest Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €7.78. Therefore, Quest Diagnostics's PE Ratio (TTM) for today is 23.27.
Warning Sign:
Quest Diagnostics Inc stock PE Ratio (=22.95) is close to 10-year high of 24.22.
The historical rank and industry rank for Quest Diagnostics's PE Ratio (TTM) or its related term are showing as below:
FRA:QDI'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 7.95 Med: 18.97 Max: 24.22
Current: 22.95
During the past 13 years, the highest PE Ratio (TTM) of Quest Diagnostics was 24.22. The lowest was 7.95. And the median was 18.97.
FRA:QDI's PE Ratio (TTM) is ranked better than 64.89% of 94
companies
in the Medical Diagnostics & Research industry
Industry Median: 31.845
vs FRA:QDI: 22.95
During the past 12 months, Quest Diagnostics's average EPS without NRIGrowth Rate was 6.70% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -0.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -6.00% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 8.30% per year.
During the past 13 years, Quest Diagnostics's highest 3-Year average EPS without NRI Growth Rate was 92.10% per year. The lowest was -14.40% per year. And the median was 9.30% per year.
Quest Diagnostics's EPS (Basic) for the
three
months ended in Mar. 2026 was €1.96.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €7.88.
Quest Diagnostics (FRA:QDI) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Quest Diagnostics PE Ratio (TTM) Related Terms
Quest Diagnostics PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Quest Diagnostics's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Quest Diagnostics's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Diagnostics PE Ratio (TTM) vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Quest Diagnostics's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Quest Diagnostics's Share Price of today is €181.10.
Quest Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.78.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Quest Diagnostics (FRA:QDI) has a PE Ratio (TTM) of 23.27 as of Jul. 21, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Quest Diagnostics and its competitors. This is 23% above median its historical median of 18.97. Over the past decade, Quest Diagnostics' PE Ratio (TTM) has ranged from 7.95 to 24.22. According to the industry distribution chart, Quest Diagnostics ranks #33 out of 94 companies in the Medical Diagnostics & Research industry, placing it in the top 35.1%.
Is Quest Diagnostics' PE Ratio (TTM) too high?
Quest Diagnostics' current PE Ratio (TTM) of 23.27 is 23% above median its 10-year median of 18.97. Over the past 10 years, this metric has ranged from a low of 7.95 to a high of 24.22. The Medical Diagnostics & Research industry median PE Ratio (TTM) is 31.85. Quest Diagnostics' value of 23.27 is 26.9% below this industry median. Based on the distribution chart, Quest Diagnostics ranks #33 out of 94 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Quest Diagnostics has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' PE Ratio (TTM) compare to LH and MTD?
According to the Medical Diagnostics & Research industry distribution chart, Quest Diagnostics ranks #33 out of 94 companies for PE Ratio (TTM). This puts Quest Diagnostics in the upper half of its industry. The industry median PE Ratio (TTM) is 31.85. Quest Diagnostics' value of 23.27 is 26.9% below this benchmark. Historically, Quest Diagnostics' own PE Ratio (TTM) has ranged from 7.95 to 24.22 over the past decade. While the company's 10-year median is 18.97 vs. the industry median of 31.85, Quest Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Medical Diagnostics & Research company?
The median PE Ratio (TTM) among Medical Diagnostics & Research companies is 31.85, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Diagnostics's current PE Ratio (TTM) of 23.27 is 26.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Quest Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median PE Ratio (TTM) is 31.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Diagnostics's current PE Ratio (TTM) is 23.27, which is 23% above median its own 10-year median of 18.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (FRA:QDI) is currently considered Fairly Valued. The stock's GF Value™ is €166.27, compared to a current price of €181.10 — trading 8.9% above its estimated fair value. The current PE Ratio (TTM) is 23.27, which is 23% above median its 10-year median of 18.97 and 26.9% below the Medical Diagnostics & Research industry median of 31.85. Quest Diagnostics' overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Quest Diagnostics (FRA:QDI), the current PE Ratio (TTM) is 23.27 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Quest Diagnostics (FRA:QDI) Overvalued in 2026?
Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued.
The current stock price of €181.10 is trading 8.9% above its estimated GF Value™ of €166.27.
GuruFocus considers Quest Diagnostics to be Fairly Valued.
Key valuation signals for FRA:QDI:
PE Ratio (TTM): 23.27 (23% above median its 10-year median of 18.97)
GF Value™: €166.27 vs. price of €181.10 (8.9% above fair value)
Industry Position: 26.9% below the Medical Diagnostics & Research median (#33 of 94)
No single metric tells the full story. See the FRA:QDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
78GF Score
Get the complete analysis for FRA:QDI
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:QDI has been successfully added to your 
